Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations

被引:124
|
作者
Gourh, Pravitt [1 ]
Arnett, Frank C. [1 ]
Assassi, Shervin [1 ]
Tan, Filemon K. [1 ]
Huang, Mei [1 ]
Diekman, Laura [1 ]
Mayes, Maureen D. [1 ]
Reveille, John D. [1 ]
Agarwal, Sandeep K. [1 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Rheumatol & Clin Immunogenet, Houston, TX 77030 USA
关键词
SOLUBLE IL-6 RECEPTOR; NECROSIS-FACTOR-ALPHA; T-LYMPHOCYTES; SERUM-LEVELS; INTERLEUKIN-6; IL-6; GAMMA LEVELS; ONCOSTATIN M; SCLERODERMA; CELLS; DISEASE;
D O I
10.1186/ar2821
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Systemic sclerosis (SSc) (scleroderma) is a complex autoimmune disease that clinically manifests as progressive fibrosis of the skin and internal organs. Anti-centromere antibodies (ACAs), anti-topoisomerase antibodies (ATAs), and anti-RNA polymerase III antibodies (ARAs) are three mutually exclusive SSc-associated autoantibodies that correlate with distinct clinical subsets characterized by extent of cutaneous involvement and pattern of organ involvement. The current report sought to determine whether plasma cytokine profiles differ in SSc patients grouped according to these SSc-associated autoantibody subsets. Methods Plasma from 444 SSc patients and 216 healthy controls was obtained from the Scleroderma Family Registry and University of Texas Rheumatology Division. Patients were classified according to the presence of ACAs, ATAs, ARAs, or none of the above (antibody-negative). Levels of 13 cytokines were determined using multiplex assays. Results Compared with females, healthy control males had higher plasma levels of IL-2 (P = 0.008), IL-5 (P = 0.01) and IL-8 (P = 0.01). In addition, in controls, IL-6 (P = 0.02) and IL-17 (P = 0.01) levels increased with advancing age. After adjusting for age and gender, SSc patients had higher circulating levels of TNF alpha (P < 0.0001), IL-6 (P < 0.0001), and IFN gamma (P = 0.05) and lower IL-17 (P = 0.0005) and IL-23 (P = 0.014). Additional analyses demonstrated that disease duration also influenced these cytokine profiles. IL-6 was elevated in ATA-positive and ARA-positive patients, but not in ACA-positive patients. IL-8 was uniquely increased in the ATA-positive subset while both ATA-positive and ACA-positive subsets had elevated IFN gamma and IL-10. IL-5 was only significantly increased in the ACA-positive subset. Lastly, patients with interstitial lung disease had elevated IL- 6 and patients with pulmonary hypertension had elevated IL- 6 and IL-13. Conclusions Plasma cytokine profiles differ in SSc patients based on the presence of SSc-associated autoantibodies. Plasma cytokine profiles in SSc patients may also be affected by disease duration and the pattern of internal organ involvement.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Clinical and autoantibody profiles of systemic sclerosis patients: A cross-sectional study from North India
    Ghosh, Shounak
    Tanna, Dhaval
    Telang, Kaustubh
    Dhuria, Shahzeene
    Gupta, Rajiva
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2024, 90 (04): : 440 - 446
  • [32] Clinical manifestations of a series of patients with systemic sclerosis
    Rodriguez Echegoyen, Dalgis Ruth
    Lopez Mantecon, Ana Marta
    Pozo Abreu, Silvia Maria
    Mederos Castellanos, Ailyn
    Martinez Larrarte, Jose Pedro
    REVISTA CUBANA DE REUMATOLOGIA, 2023, 25 (01):
  • [33] Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
    Parodis, Ioannis
    Akerstrom, Emil
    Sjowall, Christopher
    Sohrabian, Azita
    Jonsen, Andreas
    Gomez, Alvaro
    Frodlund, Martina
    Zickert, Agneta
    Bengtsson, Anders
    Ronnelid, Johan
    Gunnarsson, Iva
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [34] Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations
    McNearney, T. A.
    Sluka, K. A.
    Ahn, C.
    Reveille, J. D.
    Fischbach, M.
    Mayes, M. D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S7 - S11
  • [35] Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
    Parodis, Ioannis
    Akerstrom, Emil
    Sjowall, Christopher
    Sohrabian, Azita
    Jonsen, Andreas
    Gomez, Alvaro
    Frodlund, Martina
    Zickert, Agneta
    Bengtsson, Anders A.
    Roennelid, Johan
    Gunnarsson, Iva
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (10)
  • [36] Subclinical atherosclerosis in systemic sclerosis: Different risk profiles among patients according to clinical manifestations
    Sciarra, Iliana
    Vasile, Massimiliano
    Carboni, Alessia
    Stefanantoni, Katia
    Iannace, Nicoletta
    Angelelli, Carlotta
    Scarno, Antongiulio G.
    Valesini, Guido
    Riccieri, Valeria
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 (04) : 502 - 509
  • [37] Systemic Sclerosis in Zimbabwe: Autoantibody Biomarkers, Clinical, and Laboratory Correlates
    Sibanda, Elopy N.
    Dube, Yvonne
    Chakawa, Mazvita
    Mduluza, Takafira
    Mutapi, Francisca
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [38] CLINICAL PERFORMANCE OF A MULTIPARAMETRIC AUTOANTIBODY PROFILE IN SYSTEMIC SCLEROSIS PATIENTS
    Perez-Isidro, A.
    Lledo, G. M.
    Prieto-Gonzalez, S.
    Hernandez-Gonzalez, F.
    Andalucia, C.
    Aure, M. A.
    Cortina, A.
    Mahler, M.
    Espinosa, G.
    Vinas, O.
    Ruiz-Ortiz, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 580 - 580
  • [39] Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
    Utz, Paul J.
    Ayoglu, Burcu
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [40] Autoantibody profiles predict esophageal involvement in patients with progressive systemic sclerosis (PSS)
    Haars, P
    Kuhlbusch, R
    Haussinger, D
    Frieling, T
    GASTROENTEROLOGY, 1999, 116 (04) : A179 - A179